C. R. Bard's Lutonix technology center has completed enrolling patients in its pivotal investigational device exemption (IDE) LEVANT 2 trial, designed to evaluate Lutonix drug coated PTA dilatation catheter (DCB) as a treatment for ...
Tags: pivotal investigational device, drug coated PTA dilatation catheter